Skip to main content
Log in

Biochemical Markers of Fibrosis in Patients with Chronic Hepatitis C: A Comparison with Prothrombin Time, Platelet Count, and Age–Platelet Index

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

As an alternative to liver biopsy, an index of five biochemical markers (α2-macroglobulin, apolipoprotein A1, haptoglobin, total bilirubin, γ-glutamyl-transpeptidase) has been shown to predict the severity of hepatitis C-related fibrosis. The objective of this study was to compare this index with other markers frequently used for this purpose (prothrombin time, platelets, age–platelet index). In 323 hepatitis C-infected patients, the discriminative values of these markers for F2–F4 fibrosis (by the METAVIR classification) were compared. By multiple logistic regression analysis, only the five-marker index (P < 0.0001) and prothrombin time (P = 0.02) were independently predictive of F2–F4 fibrosis. For this outcome, the area under the receiver operating characteristic curve was significantly higher for the five-marker index (0.836 ± 0.024) than the age-platelet index (P = 0.002), and the platelet count and prothrombin time (P < 0.001), indicating greater diagnostic value. The addition of the latter markers to the five-marker index proved unhelpful for increasing its accuracy. In conclusion, an index of five biochemical markers accurately predicts significant hepatitis C-related fibrosis and is superior to traditional markers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med;345:41-52, 2001

    Google Scholar 

  2. Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E, Liddle C: Which patients with hepatitis C develop liver complications? Hepatology 31:513-520, 2000

    Google Scholar 

  3. Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology;26:57S-61S, 1997

    Google Scholar 

  4. EASL International Consensus Conference on Hepatitis C: Paris, February 26-27, 1999. Consensus statement. J Hepatol 31:3-8, 1999

  5. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 32:477-481, 2000

    Google Scholar 

  6. Froehlich F, Lamy O, Fried M, Gonvers JJ: Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 38:1480-1484, 1993

    Google Scholar 

  7. McGill DB, Rakela J, Zinsmeister AR, Ott BJ:A21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99:1396-1400, 1990

    Google Scholar 

  8. Perrault J, McGill DB, Ott BJ, Taylor WF: Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74:103-106, 1978

    Google Scholar 

  9. Friedman SL, Maher JJ, Bissell DM: Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 32:1403-1408, 2000

    Google Scholar 

  10. Friedman SL: Evaluation of fibrosis and hepatitis C. Am J Med 107:27S-30S, 1999

    Google Scholar 

  11. Park GJ, LinBP, Ngu MC, Jones DB, Katelaris PH: Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 15:386-390, 2000

    Google Scholar 

  12. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ: Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 5:187-192, 1998

    Google Scholar 

  13. Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 44:624-630, 1999

    Google Scholar 

  14. Poynard T, Bedossa P: Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 4:199-208, 1997

    Google Scholar 

  15. PoynardT, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, Chaput JC: A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 100:1397-1402, 1991

    Google Scholar 

  16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069-1075, 2001

    Google Scholar 

  17. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293, 1996

    Google Scholar 

  18. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26:2S-10S, 1997

    Google Scholar 

  19. Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843, 1983

    Google Scholar 

  20. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34:730-739, 2001

    Google Scholar 

  21. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832, 1997

    Google Scholar 

  22. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, Fujimoto J: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5:226-230, 1999

    Google Scholar 

  23. Guillen MI, Gomez-Lechon MJ, Nakamura T, Castell JV: The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on interleukin-6-stimulated genes. Hepatology 23:1345-1352, 1996

    Google Scholar 

  24. Bacq Y, Schillio Y, Brechot JF, De Muret A, Dubois F, Metman EH: Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol 17:364-369, 1993

    Google Scholar 

  25. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum Buschenfelde KH, Blessing M: TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 276:G1059-1068, 1999

    Google Scholar 

  26. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR: Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31:828-833, 2000

    Google Scholar 

  27. Tiggelman AM, Boers W, Moorman AF, de Boer PA, Van der Loos CM, Rotmans JP, Chamuleau RA: Localization of alpha 2-macroglobulin protein and messenger RNA in rat liver fibrosis: evidence for the synthesis of alpha 2-macroglobulin within Schistosoma mansoni egg granulomas. Hepatology 23:1260-1267, 1996

    Google Scholar 

  28. Kawser CA, Iredale JP, Winwood PJ, Arthur MJ: Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Colch) 95:179-186, 1998

    Google Scholar 

  29. Albanis E, Friedman SL: Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 5:315-334, v-vi, 2001

    Google Scholar 

  30. Bedossa P, Poynard T, Abella A, Aubert A, Pignon JP, Naveau S, Leluc R, Lemaigre G, Martin ED, Chaput JC: Apolipoprotein AI is a serum and tissue marker of liver fi-brosis in alcoholic patients. Alcohol Clin Exp Res 13:829-833, 1989

    Google Scholar 

  31. Paradis V, Mathurin P, Ratziu V, Poynard T, Bedossa P: Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Hepatology 23:1232-1238, 1996

    Google Scholar 

  32. Myers RP, Benhamou Y, Bochet M, Imbert-Bismut F, Thibault V, Ratziu V, Charlotte F, Katlama C, Poynard T: Serum biochemical markers of liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients. J Hepatol 36:A50, 2002 (abstract)

    Google Scholar 

  33. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. The GERMED cyt-04 group. J Viral Hepat 9:128-133, 2002

    Google Scholar 

  34. Adams L, Rossi E, DeBoer B, Speers D, Macquillan G, Garas G, Jeffrey G: Use of fibrotest to predict liver fibrosis in hepatitis C: A replacement for liver biopsy? Gastroenterology, 122:159A, 2002 (abstract)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Myers, R.P., de Torres, M., Imbert-Bismut, F. et al. Biochemical Markers of Fibrosis in Patients with Chronic Hepatitis C: A Comparison with Prothrombin Time, Platelet Count, and Age–Platelet Index. Dig Dis Sci 48, 146–153 (2003). https://doi.org/10.1023/A:1021702902681

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021702902681

Navigation